Compare Crispr Therapeutics AG (CRSP) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Manchester United PLC — how do they compare? Crispr Therapeutics AG trades at $53.37 (market cap $4.88B), while Manchester United PLC trades at $20.52 (market cap $3.51B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Manchester United PLC for 109 Days on average.
| CRSP | MANU | |
|---|---|---|
Market Cap | $4.88B | $3.51B |
Volume | 2,861,747 | 412,769 |
Sector | Health | Media |
52-Week High | $74.92 | $24.19 |
52-Week Low | $44.34 | $15.20 |
Typical Hold Time | 77 Days | 109 Days |
Enterprise Value | $3.30B | $4.33B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Manchester United (MANU) trades at $20.51, up 1.28% with a bearish technical outlook. The company reported mixed Q4 2026 results, missing EPS estimates but beating revenue expectations. Despite posting a net loss of $33.02M in 2025, revenue grew to $666.51M. Analyst sentiment is divided with 40% buy ratings, while institutional ownership shows confidence with Gabelli Funds increasing its stake by 26.2% in Q1 2026.
MANU presents a speculative opportunity given its discounted valuation relative to franchise worth, but faces significant profitability challenges. The stock's upside depends on operational improvements and Champions League performance, while persistent losses and high debt levels remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
